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However, regarding the risk of chronic rejection the longterm outcome of tissue composite transplant is not known. The decision to include BM cell infusions in the first human facial allotransplantation was based on studies where immunosuppression combined with the infusion of donor BM cells after graft organs led to a decrease in chronic rejection and an improvement of long-term graft survival. 2 However, the number of BM cells and preparative conditioning regimen required to induce tolerance of transplant organ have not been determined yet. We are reporting the results of BM infusion associated with a facial transplantation and discussing the characteristics of these cells and their potential role.
The patient, a 38-year-old woman, was bitten by her dog on the face generating severe tissue amputations as described previously. 3 Although human face transplantation was being discussed, the transplantation team decided to infuse BM recovered from the same donor.
The donor was a 46-year-old brain-dead woman. She was treated by neuroleptics. The donor and recipient had the same blood group (O þ ) and shared five HLA antigens (the donors are as follows: HLA A2-3, B8-44 and DR3-15; and the recipients are as follows: HLA A2-3, B8-44 and DR3-7).
Several minutes before the donor face dissection, 2.43 Â 10 10 total nucleated cells (TNC) (4.86 Â 10 8 TNC/ kg of the recipient's weight) were recovered from posterior iliac crests. This was an appropriate amount of cells to allow two infusions of BM as compared to usual cell numbers infused in haematopoietic BM or combined (BM/organ) transplantations. 4 In addition, the number and viability (7AAD) of TNC recovered were similar to those usually obtained in our unit (Table 1) . However, a low number of CD34 þ cells was obtained (0.42 Â 10 6 /kg) and their quality demonstrated later (results were obtained 13 days after the beginning of the cultures) was suspiciously poorer than expected with low colony forming unitsgranulocyte-macrophage (CFU-GM) growth (7 Â 10 4 /kg). Buffy coat was extracted and separated in two equal parts, which were cryopreserved.
According to Miller's procedure used in renal and BM co-transplantation, 2 half of the total BM cells were infused on days þ 4 and þ 11 after the face allotransplantation without clinical side effects. Despite the absence of problem during recovery, cryopreservation and thawing, the number of CFU-GM and viable infused CD34 þ cells for both grafts (Table 2) were lower than the mean number of CFU-GM and CD34 þ cells usually infused during allogeneic haematopoietic transplantations from our cell processing unit (CFU-GM, 35 ± 25 Â 10 4 /kg and CD34 þ cells, 2.64 ± 1.44 Â 10 6 /kg). Initial immunosuppressive drug consisted in thymoglobulines from days 0 to þ 10, mycophenolate mofetil, tacrolimus and corticosteroids. 3 Post transplant blood (CD3 þ , CD56 þ , CD15 þ cells and whole blood) chimerism assessed at days þ 8, þ 14, þ 26, þ 39, þ 53 and months 3, 4, 6 and 12 and BM (CD34 þ cells and whole BM) chimerism measured at days þ 14 and þ 26; and months 2, 3, 6 and 12 after face allotransplantation were performed via short tandem repeats (STRs) and RQ-PCR (Taqman technology whose sensitivity threshold and microchimerism were determined, respectively, by at least 0.1% and by 1% or less of donor cells). During a 1-year follow-up, microchimerism was shown only once, that is, 2 months after the face transplantation when the PCR study showed 0.1% of donor cells among the CD34 þ enriched BM population, which is the maximum chimerism ever detected in this patient. The recipient was examined each week, developed no GVHD and had only two episodes of biopsy proven mild skin (consisting in mild diffuse erythematous face lesions) and mucosa rejection at day þ 18 and month 6 which were easily resolved with high dosages of corticosteroids.
In deceased donors, BM can be recovered either from iliac crest 5 or from vertebral bodies 2 where higher numbers of TNC are collected. 6 CFU-GM growth ability is similar at both sites. 6 When vertebra are the recovering site, BM must be recovered after organs, which requires an extended processing time whereas haematopoietic stem cells (HSC) must be recovered within 2 h after disconnecting the respirator to preserve their quality. 7 In recipients of living-related donor kidney, infusions of fourfold fewer iliac crest BM cells induced a more rapid increase of chimerism than expected from previous results after infusion of vertebral BM cells. 4 Therefore, we decided to recover BM from iliac crest before other organs. In comparison with studies in living-related-donor combined BM/kidney transplantation using iliac crests for recovery, 4 the number of TNC recovered seemed appropriate. In addition, BM cells recovered from living-related or deceased donor iliac crest led to partial haematopoietic engraftment demonstrated by an early and durable microchimerism in recipients 4, 5 suggesting that the harvesting site does not explain the poor HSC quality observed in our case. Neither the delay between recovery and cryopreservation nor the absence of a special transport medium could have been implicated in the poor BM quality since cell viability performed at arrival in our laboratory was nearly 100%. Quality of HSC could have been influenced by intensive care parameters (for example, hemodynamic disturbances). In addition, the neuroleptic treatment of the donor could have contributed to these results. 8 Clinical factors affecting HSC quality must be studied to improve the quality of BM cells recovered in brain-dead patients.
Relationship between chimerism and tolerance induction remains unclear. In haematological transplantations reduced intensity conditioning regimen (RIC) induces macrochimerism and HSC engraftment that produces all its lineages. A new immune system develops in the recipients and newly developing T lymphocytes that recognize the donor antigens are clonally deleted in the thymus. The induction of tolerance and macrochimerism after combined BM/kidney transplantation for patients with multiple myeloma were demonstrated by using RIC before transplantations with the risk of developing GVHD. 9 In organ transplantation, without BM, microchimerism can be found only in one-third of long-term successful patients 10 whereas rejection can occur despite establishment of microchimerism. Whether peripheral microchimerism can induce tolerance or whether it is only one of its side effects is still debated. However, most studies about BM/ kidney transplantations show a similar low incidence of acute or chronic rejection and increased kidney life duration. 2, 4 In addition, in composite tissue allograft such as hand transplantation, despite the high immunogenicity of the skin, only few episodes of mild acute skin rejection were observed and no chronic rejection has been described so far. These observations might be related to the donor HSC contained in the associated transplanted bone tissue. 1 It is also worth noting that despite the fact that microchimerism levels and its delay of occurrence may vary and seem not related to BM cell amount and harvesting site, blood and marrow chimerism can be durably several fold higher after BM/kidney transplantation as compared to kidney transplantation alone even without any conditioning regimen, which reflects minor HSC engraftment. 2 The above-mentioned reasons and the fact that BM cells included in bone grafted in composite tissues or BM cells grafted in combined BM/organ could have participated in decreasing rejections prompted us to use donor BM cells during allogeneic face transplantation. In addition, this approach does not induce adverse immune complications like GVHD.
The absence of a durable donor chimerism in our case can be explained by an insufficient haematopoietic engraftment (because of poor HSC quality or depletion of T cells included in BM by i.v. anti-thymocytes globulins) or insufficient conditioning regimen. Although only a transient minor microchimerism was found, clinical follow-up with only two episodes of mild skin rejections suggest that BM cells could have participated in the favourable evolution observed in the patient 2 years after combined BM/face transplantation and reinforces the use of such an approach in the next face allografts. Appropriate Letter to the Editor
